Related Experiment Video
Updated: Apr 19, 2026
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A
S M Hashemi1, K Fischer1,2, K G M Moons1
1Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands.
Insights
In previously untreated patients with severe hemophilia A, a new model predicts inhibitor development. This model uses family history, F8 gene mutation, and intensive treatment details to guide therapy and reduce inhibitor risk.
Area of Science:
- Hematology
- Immunology
- Genetics
Background:
- Inhibitor formation complicates treatment for previously untreated patients (PUPs) with severe hemophilia A.
- Accurate prediction of high-risk PUPs is crucial for modifying treatment strategies to minimize inhibitor occurrence.
Purpose of the Study:
- To develop and validate an improved prediction model for inhibitor development in PUPs with severe hemophilia A.
- To create a clinical nomogram for assessing inhibitor risk based on treatment parameters.
Main Methods:
- A multicenter cohort study of 825 PUPs with severe hemophilia A (FVIII < 0.01 IU/mL) was conducted.
- Patients were followed for inhibitor development up to 50 exposure days (EDs).
- Multivariable logistic regression analyzed existing and new predictors, including F8 gene mutation, family history, and intensive treatment variables (dose and EDs).
Main Results:
- 225 out of 825 (28%) PUPs developed inhibitors.
- Independent predictors of inhibitor development included family history of inhibitors, F8 gene mutation, and an interaction of dose and number of EDs of intensive treatment.
- The prediction model achieved an AUC of 0.69 (95% CI 0.65-0.72) with good calibration.
Conclusions:
- An improved prediction model and nomogram for inhibitor development in severe hemophilia A PUPs were developed.
- The model incorporates treatment intensity (dose and duration) to allow for risk assessment and potential treatment modification.
- This tool aids clinicians in managing treatment decisions to mitigate inhibitor risk in high-risk individuals.
Abstract:
Treatment of previously untreated patients (PUPs) with severe haemophilia A is complicated by the formation of inhibitors. Prediction of PUPs with high risk is important to allow altering treatment with the intention to reduce the occurrence of inhibitors. An unselected multicentre cohort of 825 PUPs with severe haemophilia A (FVIII<0.01 IU mL(-1) ) was used. Patients were followed until 50 exposure days (EDs) or inhibitor development. All predictors of the existing prediction model including three new potential predictors were studied using multivariable logistic regression. Model performance was quantified [area under the curve (AUC), calibration plot] and internal validation (bootstrapping) was performed. A nomogram for clinical application was developed. Of the 825 patients, 225 (28%) developed inhibitors. The predictors family history of inhibitors, F8 gene mutation and an interaction variable of dose and number of EDs of intensive treatment were independently associated with inhibitor development. Age and reason for first treatment were not associated with inhibitor development. The AUC was 0.69 (95% CI 0.65-0.72) and calibration was good. An improved prediction model for inhibitor development and a nomogram for clinical use were developed in a cohort of 825 PUPs with severe haemophilia A. Clinical applicability was improved by combining dose and duration of intensive treatment, allowing the assessment of the effects of treatment decisions on inhibitor risk and potentially modify treatment.
More Related Videos
09:35Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
Published on: February 2, 2018
06:59The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:29Pharmacogenomics: Identification of New Drug Targets
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...